Assessing Tumor Response and IMRT Treat Plan After IC Based on FDG-PET/CT for Locally Advanced HNSCC

Inclusion Criteria:

• Male or female patients aged 18 years or over;
• Histologically confirmed locally advanced (stage III and IV) head and neck squamous cell carcinoma (HNSCC);
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;
• Signed written informed consent approved by the Lithuanian Bioethics Committee (LBEC);

Exclusion Criteria:

• Positive serum pregnancy test in women of childbearing potential or breastfeeding;
• Presence of distant metastasis;
• Second primary tumor;
• History of other malignancy within the last 5 years;
• Recurrent head and neck cancer;
• Serious uncontrolled concomitant disease that would contraindicate the use of any drugs use in this study as chemotherapy or radiotherapy; ;

• Inadequate organ function, evidenced by the following laboratory results:

  1. Absolute neutrophil count <1,500 cells/mm3;
  2. Platelet count <100,000 cells/mm3;
  3. Hemoglobin <9 g/dL;
  4. Total bilirubin greater than the upper limit of normal (ULN);
  5. AST (SGOT) or ALT (SGPT) >1,5 x ULN;
  6. Alkaline phosphatase levels >2,5 x the ULN;
  7. Serum creatinine >2,0 mg/dl or 177 umol/l.